Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers
January 04 2023 - 7:00AM
Business Wire
- New strategic partnership aims to broaden
access to Biognosys’ leading CRO services and Spectronaut® software
tools for unbiased proteomics and epiproteomics
- Expected to benefit proteomics research, disease biomarker
discovery, drug discovery and development, and clinical trials
leveraging pharmacoproteomics
- With Bruker investments, Biognosys plans to open advanced US
proteomics CRO facility for proteomics biomarker and drug discovery
and development, and pharmacoproteomics clinical trial
support
Bruker Corporation (Nasdaq: BRKR) and Switzerland-based
Biognosys AG today announced a strategic partnership, in which
Bruker has made a majority-ownership investment in Biognosys.
Financial details were not disclosed. J.P.Morgan acted as exclusive
financial advisor to Biognosys. Several of Biognosys’ earlier
investors have sold their shares to Bruker in a secondary
transaction, and Bruker will make new primary investments in
Biognosys.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230104005188/en/
Biognosys is a leading provider of
unbiased proteomics CRO services (Photo: Business Wire)
Co-Founder and CEO Dr. Oliver Rinner and his leadership team
will continue to manage Biognosys as a world-leading proteomics and
proteogenomics CRO services and proteomics software company. Going
forward, Biognosys’ biomarker and biopharma customers will benefit
from additional services and footprint in the US. Biognosys will
access Bruker’s leading 4D proteomics timsTOF technology for
deeper, unbiased high-precision proteomics that is not impaired by
epitope cross-reactivity - all with higher throughput and excellent
reproducibility.
Biognosys' mass spectrometry-based proteomics solutions help CRO
services and proteomics software customers in uncovering
connections between genome, transcriptome, and phenotype to explore
the static and dynamic nature of disease biology. In particular,
the Biognosys TrueTarget™, TrueDiscovery™, and TrueSignature™
research service solutions provide deep, peptide-level proteome
insights for drug discovery and development:
- TrueTarget™ uniquely addresses pressing challenges in drug
discovery by identifying on- and off-target effects, and
characterizing binding sites.
- TrueDiscovery™, powered by Spectronaut® proteomics software,
offers unbiased, multi-dimensional insights into the expression,
function, and structure of up to 4,200 proteins in plasma, up to
11,000 proteins in other biofluids, and up to 13,800 proteins in
tissue or cell lines.
- TrueSignature™ high-precision, customizable, multiplex panels
enable simultaneous absolute quantification of proteins for
pharmacodynamic readouts and clinical biomarker monitoring, in
support of pharmacoproteomics-enhanced clinical trials.
The Bruker-Biognosys collaboration is expected to create unique
synergies between Biognosys’ versatile portfolio of proprietary
proteomics services, software and kits, and Bruker’s pioneering
timsTOF platform. As a result of the strategic partnership,
Biognosys plans to open its first advanced proteomics CRO services
laboratory in the United States.
Dr. Oliver Rinner, CEO and Co-Founder of Biognosys, commented:
"We are pleased to partner with Bruker to leverage our unique
synergies to enable customers to explore the depth of the proteome
from early research to clinical development. We have worked closely
with Bruker to support dia-PASEF® high-throughput, deeper
proteomics methods within our Spectronaut® software. Biognosys
remains committed to maintaining Spectronaut® as a high-performance
vendor-agnostic proteomics software. We plan to establish our US
CRO lab in Massachusetts using the timsTOF platform, so that our
customers can benefit from multiple MS technologies.”
Dr. Rohan Thakur, President of the Bruker Life-Science Mass
Spectrometry division, said: “We are delighted to partner with
Biognosys to expand our CRO business in the US. We have many common
biomarker and biopharma customers, and even more potential
customers may prefer a proteomics CRO services expert like
Biognosys for rapid, highest quality and flexible insertion of
proteomics into their biomarker or biopharma discovery and
development. With the rapid scientific acceptance of dia-PASEF®
workflows, our partnership offers a unique combination of
proteomics applications and data-science expertise, which can
benefit more biopharma and diagnostics companies in using unbiased
proteomics for decision-making.”
Professor emeritus and proteomics pioneer Dr. Ruedi Aebersold
added: “For over a decade, ETH spin-off Biognosys has translated
novel proteomics methods pioneered in our research group into
robust, high-performance workflows for large-scale basic and
translational research. I am delighted that this new partnership
between Biognosys and Bruker will further accelerate access to high
performance proteomics. It will also provide opportunities to
develop next-generation technology and methods to determine
unexplored but functionally relevant dimensions of the proteome,
such as the modulation of proteoform composition, and protein
interaction networks as a function of cellular state.”
About Biognosys AG
At Biognosys, we believe that deep proteome insights hold the
key to breakthrough discoveries that can dramatically improve human
health. We enable life science researchers, biomarker and drug
hunters to look at the proteome from every angle with our versatile
portfolio of proprietary next-generation proteomics services,
software, and kits, including the TrueDiscovery™, TrueTarget™, and
TrueSignature™ platforms and flagship proteomics software
Spectronaut®. These solutions provide a multi-dimensional view of
protein expression, function, and structure in all biological
species and sample types. Biognosys’ unique, patented technologies
utilize high-resolution mass spectrometry to quantify thousands of
proteins across thousands of samples with industry-leading
precision, depth, and throughput. Through advanced data analytics,
Biognosys translates data into actionable insights for biomarker
and biopharma R&D, development and translational research. For
more information, visit www.biognosys.com.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular, and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity, and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. Please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230104005188/en/
Media Yves Serroen Biognosys AG Head of Marketing and
Communications T: +41 (0) 79 571 09 21 E:
yves.serroen@biognosys.com Oliver Rinner, PhD Biognosys AG Chief
Executive Office and Co-Founder T: +41 (0) 44 738 20 47 E:
oliver.rinner@biognosys.com Petra Scheffer Bruker Daltonics
Marketing Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com Investor Relations Justin Ward Sr.
Director Investor Relations & Corp Development T: +1 (978)
663–3660, ext. 1479 E: Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024